Lower drug dose after transplant may cut infections without losing protection
NCT ID NCT06001385
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant from a partially matched donor, can reduce serious infections in the first 100 days while still preventing graft-versus-host disease (a common complication where donor cells attack the patient's body). About 313 adults with various blood cancers will receive the reduced dose. The goal is to improve recovery without increasing the risk of the donor cells attacking the patient.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
-
Barnes Jewish Hospital / Washington University
St Louis, Missouri, 63110, United States
-
City of Hope
Duarte, California, 91010, United States
-
Colorado Blood Cancer Institute at Presbyterian St. Luke's
Denver, Colorado, 80218, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Emory University
Atlanta, Georgia, 30322, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Froedtert & the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Greenbaum Cancer Center University of Maryland
Baltimore, Maryland, 21201, United States
-
Honor Health
Scottsdale, Arizona, 85258, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mayo Clinic
Rochester, Minnesota, 55902, United States
-
Mayo Clinic Arizona
Phoenix, Arizona, 85054, United States
-
Mayo Clinic Jacksonville
Jacksonville, Florida, 32224, United States
-
Memorial Sloan Kettering Cancer Center - Adults
New York, New York, 10065, United States
-
Methodist Hospital San Antonio
San Antonio, Texas, 78229, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Ohio State Medical Center
Columbus, Ohio, 43210, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
St. David's South Austin Medical Center
Austin, Texas, 78704, United States
-
Stanford University
Stanford, California, 94305, United States
-
The Center for Bone Marrow Transplantation at Geisinger
Danville, Pennsylvania, 17822, United States
-
TriStar Centennial
Nashville, Tennessee, 37203, United States
-
Tufts University
Boston, Massachusetts, 02155, United States
-
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205, United States
-
University of California San Francisco
San Francisco, California, 94158, United States
-
University of Miami Sylvester Cancer Center
Miami, Florida, 33136, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
-
University of North Carolina
Chapel Hill, North Carolina, 27599, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15232, United States
-
University of Virginia Health System
Charlottesville, Virginia, 22908, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can engineered immune cells tackle brain lymphoma?